Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination

Although HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This...

Full description

Bibliographic Details
Main Authors: Nel, C, Frater, J
Format: Journal article
Language:English
Published: Frontiers Media 2024
_version_ 1826315502485504000
author Nel, C
Frater, J
author_facet Nel, C
Frater, J
author_sort Nel, C
collection OXFORD
description Although HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This has resulted in substantial investment in human studies to explore bNAbs as a curative intervention for HIV infection. Emerging data are encouraging, but suggest that combinations of bNAbs with other immunomodulatory agents may be needed to induce and sustain long-term viral control. As a result, a number of clinical trials are currently underway exploring these combinations. If successful, the impact for the millions of people living with HIV could be substantial. Here, we review the background to the use of bNAbs in the search for an HIV cure and how different adjunctive agents might be used together to enhance their efficacy.
first_indexed 2024-12-09T03:26:53Z
format Journal article
id oxford-uuid:f331eed1-5b1c-4087-bfaf-60069a8cac6c
institution University of Oxford
language English
last_indexed 2024-12-09T03:26:53Z
publishDate 2024
publisher Frontiers Media
record_format dspace
spelling oxford-uuid:f331eed1-5b1c-4087-bfaf-60069a8cac6c2024-11-30T20:03:38ZEnhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccinationJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:f331eed1-5b1c-4087-bfaf-60069a8cac6cEnglishJisc Publications RouterFrontiers Media2024Nel, CFrater, JAlthough HIV infection can be managed with antiretroviral drugs, there is no cure and therapy has to be taken for life. Recent successes in animal models with HIV-specific broadly neutralising antibodies (bNAbs) have led to long-term virological remission and even possible cures in some cases. This has resulted in substantial investment in human studies to explore bNAbs as a curative intervention for HIV infection. Emerging data are encouraging, but suggest that combinations of bNAbs with other immunomodulatory agents may be needed to induce and sustain long-term viral control. As a result, a number of clinical trials are currently underway exploring these combinations. If successful, the impact for the millions of people living with HIV could be substantial. Here, we review the background to the use of bNAbs in the search for an HIV cure and how different adjunctive agents might be used together to enhance their efficacy.
spellingShingle Nel, C
Frater, J
Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
title Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
title_full Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
title_fullStr Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
title_full_unstemmed Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
title_short Enhancing broadly neutralising antibody suppression of HIV by immune modulation and vaccination
title_sort enhancing broadly neutralising antibody suppression of hiv by immune modulation and vaccination
work_keys_str_mv AT nelc enhancingbroadlyneutralisingantibodysuppressionofhivbyimmunemodulationandvaccination
AT fraterj enhancingbroadlyneutralisingantibodysuppressionofhivbyimmunemodulationandvaccination